Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
- PMID: 9725545
- DOI: 10.1002/j.1552-4604.1998.tb04809.x
Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
Abstract
Absolute oral bioavailability and disposition characteristics of irbesartan, an angiotensin II receptor antagonist, were investigated in 18 healthy young male volunteers. Subjects received [14C] irbesartan as a 30-minute intravenous infusion (50 mg), [14C] irbesartan orally as a solution (50 mg or 150 mg), or irbesartan capsule (50 mg). Irbesartan was rapidly and almost completely absorbed after oral administration, and exhibited a mean absolute oral bioavailability of 60% to 80%. Mean total body clearance was approximately 157 mL/min, and renal clearance was 3.0 mL/min. Volume of distribution at steady state was 53 L to 93 L, and terminal elimination half-life was approximately 13 to 16 hours. Hepatic extraction ratio was low (0.2). There were no major circulating metabolites, and approximately 80% of total plasma radioactivity was attributable to unchanged irbesartan. Regardless of route of administration, approximately 20% of dose was recovered in urine and the remainder in feces.
Similar articles
-
Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.Drug Metab Dispos. 2000 Jan;28(1):79-88. Drug Metab Dispos. 2000. PMID: 10611144
-
The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.J Clin Pharmacol. 2001 Sep;41(9):935-42. doi: 10.1177/00912700122010906. J Clin Pharmacol. 2001. PMID: 11549097 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.J Clin Pharmacol. 1998 Apr;38(4):347-56. doi: 10.1002/j.1552-4604.1998.tb04434.x. J Clin Pharmacol. 1998. PMID: 9590462 Clinical Trial.
-
Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.J Hypertens Suppl. 1997 Dec;15(7):S15-20. J Hypertens Suppl. 1997. PMID: 9532516 Review.
-
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.Am J Hypertens. 1997 Dec;10(12 Pt 2):311S-317S. doi: 10.1016/s0895-7061(97)00391-9. Am J Hypertens. 1997. PMID: 9438775 Review.
Cited by
-
Inhibitory Effects of Angiotensin II Receptor Blockade on Human Tenon Fibroblast Migration and Reactive Oxygen Species Production in Cell Culture.Transl Vis Sci Technol. 2018 Apr 9;7(2):20. doi: 10.1167/tvst.7.2.20. eCollection 2018 Apr. Transl Vis Sci Technol. 2018. PMID: 29657902 Free PMC article.
-
Irbesartan: a review of its use in hypertension and diabetic nephropathy.Drugs. 2008;68(11):1543-69. doi: 10.2165/00003495-200868110-00008. Drugs. 2008. PMID: 18627212 Review.
-
Studies on jackfruit seed starch as a novel natural superdisintegrant for the design and evaluation of irbesartan fast dissolving tablets.Integr Med Res. 2017 Sep;6(3):280-291. doi: 10.1016/j.imr.2017.04.001. Epub 2017 May 26. Integr Med Res. 2017. PMID: 28951842 Free PMC article.
-
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.Drugs. 2004;64(9):999-1028. doi: 10.2165/00003495-200464090-00011. Drugs. 2004. PMID: 15101793 Review.
-
Clinical pharmacology of the angiotensin receptor antagonists.J Clin Hypertens (Greenwich). 2001 Jan-Feb;3(1):45-9. doi: 10.1111/j.1524-6175.2001.00832.x. J Clin Hypertens (Greenwich). 2001. PMID: 11416682 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources